FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092442011> ?p ?o ?g. }

• W3092442011 endingPage "313" @default.
• W3092442011 startingPage "305" @default.
• W3092442011 abstract "Tislelizumab, an anti-programmed death protein-1 (PD-1) monoclonal antibody, was engineered to minimize binding to the FcγR on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. This single-arm phase 2 trial (NCT04004221/CTR20170071) assessed the safety, tolerability, and efficacy of tislelizumab in patients with PD-L1-positive urothelial carcinoma who progressed during/following platinum-containing therapy and had no prior PD-(L)1 inhibitor treatment. Patients were considered PD-L1 positive if ≥ 25% of tumor/immune cells expressed PD-L1 when using the VENTANA™ PD-L1 (SP263) assay. The primary endpoint was objective response rate by independent review committee. As of September 16, 2019, 113 patients had a median study follow-up time of 9.4 mo. Most patients (76%) had visceral metastases, including 24% with liver and 23% with bone metastases. Among 104 efficacy-evaluable patients, confirmed objective response rate was 24% (95% confidence interval, 16, 33), including 10 complete and 15 partial responses. Median duration of response was not reached. Among 25 responders, 17/25 (68%) had ongoing responses. Median progression-free survival and overall survival times were 2.1 and 9.8 mo, respectively. The most common treatment-related adverse events were anemia (27%) and pyrexia (19%). Anemia (7%) and hyponatremia (5%) were the only grade 3-4 treatment-related adverse events and occurred in ≥ 5% of patients. Three investigator-assessed deaths were considered to be possibly related to study treatment (hepatic failure, n = 2; respiratory arrest, n = 1). Tislelizumab demonstrated meaningful clinical benefits in patients with previously treated locally advanced or metastatic PD-L1-positive urothelial carcinoma and had a manageable safety profile." @default.
• W3092442011 created "2020-10-15" @default.
• W3092442011 creator A5000239300 @default.
• W3092442011 creator A5000664175 @default.
• W3092442011 creator A5004624217 @default.
• W3092442011 creator A5008666872 @default.
• W3092442011 creator A5016318026 @default.
• W3092442011 creator A5018737199 @default.
• W3092442011 creator A5032547003 @default.
• W3092442011 creator A5039924898 @default.
• W3092442011 creator A5053347862 @default.
• W3092442011 creator A5054529993 @default.
• W3092442011 creator A5055635104 @default.
• W3092442011 creator A5056789954 @default.
• W3092442011 creator A5057056291 @default.
• W3092442011 creator A5057146015 @default.
• W3092442011 creator A5059507084 @default.
• W3092442011 creator A5062284808 @default.
• W3092442011 creator A5067643729 @default.
• W3092442011 creator A5076184087 @default.
• W3092442011 creator A5081156337 @default.
• W3092442011 creator A5083840942 @default.
• W3092442011 date "2020-11-06" @default.
• W3092442011 modified "2023-10-18" @default.
• W3092442011 title "Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma" @default.
• W3092442011 cites W1588429113 @default.
• W3092442011 cites W1950618346 @default.
• W3092442011 cites W1971821333 @default.
• W3092442011 cites W1975992327 @default.
• W3092442011 cites W2019607817 @default.
• W3092442011 cites W2098028863 @default.
• W3092442011 cites W2148562299 @default.
• W3092442011 cites W2160834915 @default.
• W3092442011 cites W2509486054 @default.
• W3092442011 cites W2546607321 @default.
• W3092442011 cites W2560367415 @default.
• W3092442011 cites W2588197185 @default.
• W3092442011 cites W2766086695 @default.
• W3092442011 cites W2771637939 @default.
• W3092442011 cites W2774605139 @default.
• W3092442011 cites W2799565954 @default.
• W3092442011 cites W2900738779 @default.
• W3092442011 cites W2905413469 @default.
• W3092442011 cites W2943108118 @default.
• W3092442011 cites W2955110013 @default.
• W3092442011 cites W2978685727 @default.
• W3092442011 cites W3012466751 @default.
• W3092442011 cites W3021977488 @default.
• W3092442011 cites W3034803562 @default.
• W3092442011 cites W3036157555 @default.
• W3092442011 cites W3092442011 @default.
• W3092442011 doi "https://doi.org/10.1111/cas.14681" @default.
• W3092442011 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7780053" @default.
• W3092442011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33047430" @default.
• W3092442011 hasPublicationYear "2020" @default.
• W3092442011 type Work @default.
• W3092442011 sameAs 3092442011 @default.
• W3092442011 citedByCount "47" @default.
• W3092442011 countsByYear W30924420112020 @default.
• W3092442011 countsByYear W30924420112021 @default.
• W3092442011 countsByYear W30924420112022 @default.
• W3092442011 countsByYear W30924420112023 @default.
• W3092442011 crossrefType "journal-article" @default.
• W3092442011 hasAuthorship W3092442011A5000239300 @default.
• W3092442011 hasAuthorship W3092442011A5000664175 @default.
• W3092442011 hasAuthorship W3092442011A5004624217 @default.
• W3092442011 hasAuthorship W3092442011A5008666872 @default.
• W3092442011 hasAuthorship W3092442011A5016318026 @default.
• W3092442011 hasAuthorship W3092442011A5018737199 @default.
• W3092442011 hasAuthorship W3092442011A5032547003 @default.
• W3092442011 hasAuthorship W3092442011A5039924898 @default.
• W3092442011 hasAuthorship W3092442011A5053347862 @default.
• W3092442011 hasAuthorship W3092442011A5054529993 @default.
• W3092442011 hasAuthorship W3092442011A5055635104 @default.
• W3092442011 hasAuthorship W3092442011A5056789954 @default.
• W3092442011 hasAuthorship W3092442011A5057056291 @default.
• W3092442011 hasAuthorship W3092442011A5057146015 @default.
• W3092442011 hasAuthorship W3092442011A5059507084 @default.
• W3092442011 hasAuthorship W3092442011A5062284808 @default.
• W3092442011 hasAuthorship W3092442011A5067643729 @default.
• W3092442011 hasAuthorship W3092442011A5076184087 @default.
• W3092442011 hasAuthorship W3092442011A5081156337 @default.
• W3092442011 hasAuthorship W3092442011A5083840942 @default.
• W3092442011 hasBestOaLocation W30924420111 @default.
• W3092442011 hasConcept C126322002 @default.
• W3092442011 hasConcept C143998085 @default.
• W3092442011 hasConcept C197934379 @default.
• W3092442011 hasConcept C203092338 @default.
• W3092442011 hasConcept C2778248108 @default.
• W3092442011 hasConcept C2778375690 @default.
• W3092442011 hasConcept C535046627 @default.
• W3092442011 hasConcept C71924100 @default.
• W3092442011 hasConcept C90924648 @default.
• W3092442011 hasConceptScore W3092442011C126322002 @default.
• W3092442011 hasConceptScore W3092442011C143998085 @default.
• W3092442011 hasConceptScore W3092442011C197934379 @default.
• W3092442011 hasConceptScore W3092442011C203092338 @default.
• W3092442011 hasConceptScore W3092442011C2778248108 @default.

• next